One-Stop ADC
CDMO Service
ChemExpress offers integrated services spanning from Payload-Linker to ADC DS&DP, enabling efficient scale-up and seamless technology transfer, effectively reducing management and transition costs.
Extensive Project Experience
& Comprehensive Inventory
Over 80 CMC projects, 6 BLA projects, and 1 commercial project have been delivered. 16 ADC payloads and related intermediates are registered with the FDA as DMFs.
Expert Scientific
Team
Our team of over 700 scientists provides comprehensive support from R&D to commercialization, ensuring high-quality, scalable solutions for your ADC pipeline.
Our Services
With 500+ linkers in stock and 2,000+ linker synthesis experience, ChemExpress collaborates closely with clients to screen, customized synthesis, process development & optimization, clinical supply, and commercial manufacturing to support advanced research worldwide.
Our Sites
R&D Sites
ADC Payload-Linker and Conjugation R&D, Route Confirmation, Process Optimization and GLP Toxicological Batch Production. 
ADC Payload-Linkers & HPAPIs Process Development and Manufacturing.
Related Services
ADC Payload Linker
We specialize in complex and novel payload-linker, offering fully customized synthesis, process development & optimization, clinical supply, and commercial manufacturing services to meet the specific needs of client projects.
ADC Payload
Our facilities support Non-GMP & GMP payload production scales from milligram to kilogram with over 150 payloads in stock to meet diverse needs across every stage of ADC development and manufacturing.
FAQs
ChemExpress does not provide ADC linker design services, and therefore all intellectual property generated during the project remains fully owned by the client upon confirmation.
All linkers included in our internal database are publicly available structures. ChemExpress does not independently create or patent new ADC linkers, but can provide technical recommendations related to stability, compatibility, and manufacturability to support client decision-making.
The choice between a cleavable and a non-cleavable linker depends on a combination of target biology, payload mechanism of action, systemic circulation stability requirements, and desired safety profile.
· Cleavable linkers are typically selected when efficient intracellular drug release is critical, leveraging tumor-associated conditions such as enzymatic activity, acidic pH, or a reductive environment. These linkers may enable broader bystander effects but require careful control of systemic stability.
· Non-cleavable linkers are often preferred when maximum plasma stability and controlled payload retention are required. Payload release occurs primarily after antibody degradation within the target cell, which can reduce off-target toxicity and improve overall safety.
ChemExpress supports linker selection through stability screening and compatibility studies, helping clients balance efficacy, safety, and manufacturability for their ADC programs.
